Debbie Rigby takes a look at the latest in research news Oral antivirals for mild–moderate COVID‑19: a panacea or a logistical and clinical conundrum? Multiple therapeutic options for COVID-19 are now available. These include parenteral anti-spike protein monoclonal antibodies (sotrovimab, casirivimab/ imdevimab), oral antivirals (nirmatrelvir/ritonavir, molnupiravir) and parenteral antivirals (remdesivir). Among the new oral drugs,
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.